- Acadia Pharma press release (NASDAQ:ACAD): Q1 GAAP EPS of $0.11 beats by $0.02.
- Revenue of $244.3M (+18.7% Y/Y) beats by $5.33M.
- Shares +0.24%.
-
First quarter NUPLAZID® (pimavanserin) net product sales of $159.7 million, up 23% year-over-year
– First quarter DAYBUE®
Acadia Pharma GAAP EPS of $0.11 beats by $0.02, revenue of $244.3M beats by $5.33M
